Status:
UNKNOWN
Hyperuricemia and Diabetic Nephropathy
Lead Sponsor:
Assiut University
Conditions:
Hyperuricemia
Diabetic Nephropathies
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to detect the effect of treatment of hyperuricemia on eGFR (Estimated Glomerular Filtration Rate) as an objective criterion for assessment of progression of diabetic nephro...
Detailed Description
After being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. At week 0, pati...
Eligibility Criteria
Inclusion
- Patient population will include both males and females above the age of 18 years with T2DM and Diabetic Nephropathy stage 3 CKD (eGFR: 31-59).
Exclusion
- Patients with history of hypothyroidism, alcoholism, urinary tract infections, glomerulonephritis, myeloproliferative disorders and gout "as gout is a common inflammatory arthropathy characterized by painful and swollen joints resulting from precipitating uric acid crystals but hyperuricemia is commonly asymptomatic" or on drugs capable of inducing Hyperuricemia will be excluded from the study.
- Any patient will develop acute kidney injury episode at any time of the study will be excluded from the study.
- Patients with uncontrolled hypertension will be excluded from the study.
Key Trial Info
Start Date :
April 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04799925
Start Date
April 15 2021
End Date
December 30 2022
Last Update
March 16 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.